Purchase Option

$ 3000
$ 4400
$ 4000
$ 6000

Atopic Dermatitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018  

Atopic Dermatitis Pipeline Drugs Assessment

  Overview: Atopic dermatitis is a chronic, pruritic inflammatory skin disease with unknown origin. It generally occurs in children but affects a substantial number of adults.Symptoms include dry skin, itching, red to brownish-grey patches especially on hands, neck, upper feet, legs, inside the bend of elbows, knees and other parts of the body. Atopic dermatitis generally examined through the physical examination. No cure has been found for atopic dermatitis, but the treatment is given for relieving the symptoms. Treatment may include topical applications to relieve the itching, oral drugs to control the inflammation and drugs for infection control.Food and Drug Administration (FDA) has recently approved a new, injectable monoclonal antibody, dupilumab for the treatment of severe atopic dermatitis. [caption id="attachment_24172" align="alignnone" width="899"]Atopic Dermatitis Atopic Eczema Treatment Market: 2018-2024 Atopic Dermatitis Atopic Eczema Treatment Market: 2018-2024[/caption] Segmentation: By route of administration, atopic dermatitis pipeline drugs are segmented into
  • Oral
  • Topical
  • Parenteral
By Trial Phase, Atopic Dermatitis pipeline drugs are segmented as:
  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
By company, Atopic Dermatitis pipeline drugs are segmented into
  • AbbVie Inc. (U.S.)
  • Sterna Biologicals GmbH & Co. KG (Germany)
  • Santalis Pharmaceuticals, Inc. (U.S.)
  • MedImmune LLC (U.S.)
  • Eli Lilly and Company (U.S.)
  • Regeneron Pharmaceutical (U.S.)
  • Sienna Biopharmaceuticals (U.S.)
  • Others
  Space Analysis: Currently, there is no availability of effective treatments to treat atopic dermatitis. Most of the drugs are used to relieve the symptoms. Two Janus kinase inhibitors approved for rheumatoid arthritis and myelodysplasia. One of these drugs isstudied for atopic dermatitis but drug is not actively developed now. Many Janus kinase inhibitors are in clinical trial stages for treatment of atopic dermatitis.
  • In March 2017, LEO Pharma announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD).
  • In January 2017, AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation for the investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.
  Report Description: Atopic Dermatitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Atopic Dermatitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Atopic Dermatitis disease pipeline drugs development. This report studies the dynamics of the Atopic Dermatitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Atopic Dermatitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.   Key Features of the Report:
  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases
 

Location

GEOGRAPHY

PBI Location Map

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
LOCATION

Geography

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Table of Content
  2. Executive Summary
  3. Global Atopic Dermatitis Pipeline Drugs Assessment Market Introduction
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market – Taxonomy
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market –Definitions
      • Route of Administration
      • Trail Phase
  1. Global Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Atopic Dermatitis Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Atopic Dermatitis Pipeline Drugs Assessment Market, By Route of Administration, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Topical
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Atopic Dermatitis Pipeline Drugs Assessment Market Forecast, By Trail Phase,2013 - 2017 and Forecast, 2018 – 2024
    • Preclinical Trials
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Atopic Dermatitis Pipeline Drugs Assessment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Region, 2018 – 2024
  2. North America Atopic Dermatitis Pipeline Drugs Assessment MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 – 2024
    • North America Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 – 2024
    • Europe Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 – 2024
    • Asia-Pacific Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 – 2024
    • Latin America Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 – 2024
    • MEA Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AbbVie Inc. (U.S.)
      • Sterna Biologicals GmbH & Co. KG (Germany)
      • Santalis Pharmaceuticals, Inc. (U.S.)
      • MedImmune LLC (U.S.)
      • Eli Lilly and Company (U.S.)
      • Regeneron Pharmaceutical (U.S.)
      • Sienna Biopharmaceuticals (U.S.)
      • Others
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

  1. Disclaimer
  2. The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

 

  • AbbVie Inc. (U.S.)
  • Sterna Biologicals GmbH & Co. KG (Germany)
  • Santalis Pharmaceuticals, Inc. (U.S.)
  • MedImmune LLC (U.S.)
  • Eli Lilly and Company (U.S.)
  • Regeneron Pharmaceutical (U.S.)
  • Sienna Biopharmaceuticals (U.S.)